Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P31644

UPID:
GBRA5_HUMAN

ALTERNATIVE NAMES:
GABA(A) receptor subunit alpha-5

ALTERNATIVE UPACC:
P31644; A8K338; Q14DC2; Q53XL6; Q9NYT3; Q9NYT4; Q9NYT5

BACKGROUND:
The GABA(A) receptor subunit alpha-5 is integral to the GABAergic system, facilitating inhibitory neurotransmission and maintaining neuronal stability. Its role extends to receptor assembly and synaptic localization, critical for effective neural communication and plasticity.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Gamma-aminobutyric acid receptor subunit alpha-5 could open doors to potential therapeutic strategies. Its direct link to Developmental and Epileptic Encephalopathy 79 highlights the importance of this protein in developing targeted therapies for epilepsy and associated neurodevelopmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.